PMID- 27252425 OWN - NLM STAT- MEDLINE DCOM- 20171221 LR - 20180207 IS - 1499-2752 (Electronic) IS - 0315-162X (Linking) VI - 43 IP - 8 DP - 2016 Aug TI - Comorbidities in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis versus the General Population. PG - 1553-8 LID - 10.3899/jrheum.151151 [doi] AB - OBJECTIVE: To evaluate the consultation rates of selected comorbidities in patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) compared with the general population in southern Sweden. METHODS: We used data from a population-based cohort of patients with AAV diagnosed between 1998 and 2010 in Southern Sweden (701,000 inhabitants). For each patient we identified 4 reference subjects randomly sampled from the general population and matched for year of birth, sex, area of residence, and index year. Using the population-based Skane Healthcare Register, we identified relevant diagnostic codes, registered between 1998 and 2011, for selected comorbidities assigned after the date of diagnosis of AAV or the index date for the reference subjects. We calculated rate ratios for comorbidities (AAV:reference subjects). RESULTS: There were 186 patients with AAV (95 women, mean age 64.5 yrs) and 744 reference persons included in the analysis. The highest rate ratios (AAV:reference) were obtained for osteoporosis (4.6, 95% CI 3.0-7.0), followed by venous thromboembolism (4.0, 95% CI 1.9-8.3), thyroid diseases (2.1, 95% CI 1.3-3.3), and diabetes mellitus (2.0, 95% CI 1.3-2.9). For ischemic heart disease, the rate ratio of 1.5 (95% CI 1.0-2.3) did not reach statistical significance. No statistically significant differences were found for cerebrovascular accidents. CONCLUSION: AAV is associated with increased consultation rates of several comorbidities including osteoporosis and thromboembolic and endocrine disorders. Comorbid conditions should be taken into consideration when planning and providing care for patients with AAV. FAU - Englund, Martin AU - Englund M AD - From the Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, and Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund; Department of Nephrology, Linkoping University, Linkoping, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Englund, MD, PhD, Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, Lund University, and Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania; G. Tomasson, MD, Department of Public Health Sciences, University of Iceland; M. Segelmark, MD, PhD, Department of Nephrology, Linkoping University; A.J. Mohammad, MD, PhD, Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK. FAU - Merkel, Peter A AU - Merkel PA AD - From the Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, and Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund; Department of Nephrology, Linkoping University, Linkoping, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Englund, MD, PhD, Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, Lund University, and Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania; G. Tomasson, MD, Department of Public Health Sciences, University of Iceland; M. Segelmark, MD, PhD, Department of Nephrology, Linkoping University; A.J. Mohammad, MD, PhD, Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK. FAU - Tomasson, Gunnar AU - Tomasson G AD - From the Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, and Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund; Department of Nephrology, Linkoping University, Linkoping, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Englund, MD, PhD, Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, Lund University, and Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania; G. Tomasson, MD, Department of Public Health Sciences, University of Iceland; M. Segelmark, MD, PhD, Department of Nephrology, Linkoping University; A.J. Mohammad, MD, PhD, Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK. FAU - Segelmark, Marten AU - Segelmark M AD - From the Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, and Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund; Department of Nephrology, Linkoping University, Linkoping, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Englund, MD, PhD, Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, Lund University, and Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania; G. Tomasson, MD, Department of Public Health Sciences, University of Iceland; M. Segelmark, MD, PhD, Department of Nephrology, Linkoping University; A.J. Mohammad, MD, PhD, Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK. FAU - Mohammad, Aladdin J AU - Mohammad AJ AD - From the Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, and Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund; Department of Nephrology, Linkoping University, Linkoping, Sweden; Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, Massachusetts; Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Public Health Sciences, University of Iceland, Reykjavik, Iceland; the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK.M. Englund, MD, PhD, Clinical Epidemiology Unit, Orthopaedics, Clinical Sciences Lund, Lund University, and Clinical Epidemiology Research and Training Unit, Boston University School of Medicine; P.A. Merkel, MD, MPH, Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania; G. Tomasson, MD, Department of Public Health Sciences, University of Iceland; M. Segelmark, MD, PhD, Department of Nephrology, Linkoping University; A.J. Mohammad, MD, PhD, Department of Clinical Sciences, Section of Rheumatology, Lund University, Lund, and the Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge, UK. Aladdin.mohammad@med.lu.se. LA - eng PT - Journal Article DEP - 20160601 PL - Canada TA - J Rheumatol JT - The Journal of rheumatology JID - 7501984 SB - IM MH - Aged MH - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*epidemiology MH - Cohort Studies MH - Comorbidity MH - Female MH - Humans MH - Male MH - Middle Aged MH - Osteoporosis/*epidemiology MH - Sweden/epidemiology MH - Venous Thromboembolism/*epidemiology OTO - NOTNLM OT - ANCA-ASSOCIATED VASCULITIS OT - ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES OT - COMORBIDITIES OT - OUTCOME OT - POPULATION-BASED STUDY EDAT- 2016/06/03 06:00 MHDA- 2017/12/22 06:00 CRDT- 2016/06/03 06:00 PHST- 2016/04/11 00:00 [accepted] PHST- 2016/06/03 06:00 [entrez] PHST- 2016/06/03 06:00 [pubmed] PHST- 2017/12/22 06:00 [medline] AID - jrheum.151151 [pii] AID - 10.3899/jrheum.151151 [doi] PST - ppublish SO - J Rheumatol. 2016 Aug;43(8):1553-8. doi: 10.3899/jrheum.151151. Epub 2016 Jun 1.